Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome

BACKGROUND: In patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), newer antiplatelet agents prasugrel and ticagrelor have lower rates of cardiovascular events when compared with clopidogrel. However, it is unclear whether there are differences in econo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kibum, Lee, Todd A., Touchette, Daniel R., DiDomenico, Robert J., Ardati, Amer K., Walton, Surrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397951/
https://www.ncbi.nlm.nih.gov/pubmed/30058986
http://dx.doi.org/10.18553/jmcp.2018.24.8.800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397951/
https://www.ncbi.nlm.nih.gov/pubmed/30058986
http://dx.doi.org/10.18553/jmcp.2018.24.8.800

Ejemplares similares